Chlamydia is the most common bacterial sexually transmitted infection worldwide \[[@CIT0001]\]. The estimated global incidence of chlamydial infection is approximately 131 million new cases annually \[[@CIT0002]\]. Although chlamydial infection typically affects sexually active adults, it can be passed on to newborns by their infected mother during delivery. Approximately 30% to 50% of infants born to a mother with active chlamydial infection will develop neonatal conjunctivitis, also known as ophthalmia neonatorum (ON) \[[@CIT0003]\]. Infection in neonates commonly affects the conjunctivae, but it can occur also in the nasopharynx, lungs, vagina, urethra, and rectum \[[@CIT0004]\].

Neonatal conjunctivitis caused by *Chlamydia trachomatis* is an acute infection of the conjunctiva that is characterized by erythema and edema of the eyelids, palpebral conjunctivae, and purulent eye discharge. It typically occurs between 5 and 14 days after delivery, although it can present earlier \[[@CIT0005]\]. Neonatal conjunctivitis caused by *C trachomatis* is now significantly more prevalent than gonococcal conjunctivitis and has been reported to be the most common infectious cause of neonatal conjunctivitis worldwide \[[@CIT0005]\]. Although it is generally a mild illness, complications can occur if it is left untreated; cases of untreated infection resulting in complications, such as scarring of the cornea or conjunctiva, have been reported \[[@CIT0008], [@CIT0009]\]. In addition, up to 20% of neonates exposed to chlamydial infection during birth can develop pneumonia, and evidence of previous conjunctivitis is found in approximately 50% of them \[[@CIT0004], [@CIT0010]\].

Newborn ocular prophylaxis has been found to be ineffective in protecting against chlamydial conjunctivitis \[[@CIT0011], [@CIT0012]\]. Several high-income countries have abandoned ocular prophylaxis of newborns and replaced it with routine prenatal screening and treatment of mothers with a sexually transmitted infection \[[@CIT0012]\]. Indeed, the incidence of neonatal chlamydial and gonorrheal infection has decreased dramatically since the widespread initiation of routine prenatal screening and treatment of pregnant women in North America \[[@CIT0003], [@CIT0013]\]. However, in countries where prenatal screening is not a common practice and maternal chlamydial infections are prevalent, chlamydial infection remains a common cause of ON \[[@CIT0003], [@CIT0014]\]. In Hong Kong, where routine prenatal screening and treatment are not performed, an incidence of 4 cases of ON per 1000 live births between 2004 and 2005 was reported \[[@CIT0015]\]. In contrast, in the United States, where routine prenatal screening and treatment are standard of care, the overall ON rate in 2002 was 8.5 per 100000 live births \[[@CIT0016]\]. In 2015 in Canada, the rate of reported cases of chlamydial infection in children aged less than 1 year was approximately 10 per 100000 \[[@CIT0017]\]. A 2017 survey of approximately 300 pediatric ophthalmologists, primarily in North America, estimated the number of neonatal conjunctivitis cases, most commonly caused by *C trachomatis*, to be up to 5 per practitioner per year \[[@CIT0007]\]. Because of the continued high prevalence of chlamydia worldwide and the lack of prenatal screening in certain countries, a need for safe and effective therapies for infants who acquire a chlamydial infection remains. Therefore, we conducted a systematic review and meta-analysis of studies that tested antibiotic treatments, including oral erythromycin, azithromycin, or trimethoprim, for treating neonatal chlamydial conjunctivitis.

METHODS {#s5}
=======

A World Health Organization (WHO) guideline panel of clinicians, neonatologists, pathologists, researchers, and program managers with expertise in sexually transmitted infections \[[@CIT0018]\] informed our inclusion and exclusion criteria for this review. We followed the *Cochrane Handbook for Systematic Reviews of Interventions* \[[@CIT0019]\] and completed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist \[[@CIT0020]\].

Search Strategy and Study Selection {#s6}
-----------------------------------

We searched Medline, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) from their inception date to July 14, 2017. The search strategy included keywords and text words for chlamydia, ON, conjunctivitis, and the drug names. We did not impose language or study type restrictions. We also reviewed the reference lists of relevant study, guideline, and systematic review reports (see "Search Strategy" in [Supplementary Material](#sup1){ref-type="supplementary-material"}). Two investigators (A. Z. and N. S.) independently screened citations according to title and abstract and screened the full text of the relevant articles. Disagreements were resolved by consensus or by consulting with a third investigator.

We included primary studies on the effects of oral erythromycin, azithromycin, or trimethoprim in treating neonatal chlamydial conjunctivitis. Although other oral and topical antimicrobial agents are available, these 3 antimicrobials were chosen by the WHO guideline panel as a high priority for review, because they are used more widely in lower- and middle-income countries, and there is an outstanding question about which of them should be used in practice. We included any dosing regimen but were particularly interested in the effects of doses commonly used in lower- and middle-income countries, that is, erythromycin in 4 daily divided doses orally for 14 days at 20, 30, or 50 mg/kg body weight per day, azithromycin at 20 mg/kg per day orally (1 dose or for 3 days), and trimethoprim at 40 mg plus sulfa at 200 mg orally, twice daily for 14 days. We allowed randomized controlled trials and nonrandomized studies, including before--after studies, that followed 1 or 2 groups of neonates who underwent an eligible treatment. We included studies if more than 90% of the neonates were younger than 2 months at disease onset and diagnosed with chlamydial conjunctivitis on the basis of clinical symptoms and microbiological confirmation *of C trachomatis* using culture, a direct fluorescent antibody (DFA) test, or nucleic acid amplification testing (NAAT). The WHO guideline panel of experts identified critically important outcomes to include in the review by using methods for prioritizing outcomes \[[@CIT0021]\]. Outcomes included clinical cure, microbiological cure, adverse effects (including pyloric stenosis), complications, antimicrobial resistance, and compliance. We also recorded data regarding treatment relapse, nasopharyngeal infection, and pneumonia. Clinical cure was defined as the resolution of signs and symptoms of neonatal chlamydial conjunctivitis, including erythema and edema of the eyelids or conjunctiva and ocular discharge. Microbiological cure was recorded when the results of chlamydial follow-up tests determined by culture, a DFA, or NAAT were negative.

Data Extraction and Risk of Bias Assessment {#s7}
-------------------------------------------

We created and piloted a data-extraction form. One investigator extracted the data, and a second investigator verified the data. We extracted data to determine the characteristics of the study, the effects of treatments, and the risk of bias, and the risk of bias. We used the Newcastle-Ottawa Scale for nonrandomized studies, because the articles we found reported the effects of only 1 treatment with no comparison \[[@CIT0022]\]. For before--after studies of 1 treatment, we did not answer the question of comparability of the groups. We resolved disagreements by discussion between the 2 investigators

Analysis and Assessment of the Evidence {#s8}
---------------------------------------

We conducted a meta-analysis of dichotomous outcomes by using a random-effects generic inverse-variance method to calculate pooled proportions and 95% confidence intervals (CIs) in Review Manager 5.1 (Nordic Cochrane Center and the Cochrane Collaboration, Copenhagen, Denmark). Two investigators evaluated the certainty of evidence for each outcome by using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach and resolved any discrepancies \[[@CIT0023]\]. We assessed all GRADE domains, that is, risk of bias, inconsistency, imprecision, indirectness, publication bias, large effect, presence of a dose response, and plausible opposing confounders. According to the GRADE, we present the certainty of evidence as high, moderate, low, or very low \[[@CIT0024]\].

RESULTS {#s9}
=======

We found 312 nonduplicate records from our search of electronic databases and included 12 studies \[[@CIT0004], [@CIT0015], [@CIT0025]\] presented as a narrative synthesis or meta-analysis (see [Figure 1](#F1){ref-type="fig"} for the Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram).

![PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram of the study-selection process.](piy06001){#F1}

Characteristics of the Studies {#s10}
------------------------------

### Study Design and Country {#s11}

Characteristics of the included studies are summarized in [Table 1](#T1){ref-type="table"}. Of the 12 studies, 9 \[[@CIT0004], [@CIT0015], [@CIT0027], [@CIT0032]\] were nonrandomized. Three studies \[[@CIT0025], [@CIT0026], [@CIT0031]\] were randomized controlled trials; however, only 1 group in each study assessed an eligible treatment. Of the 9 nonrandomized studies, 8 collected data prospectively \[[@CIT0004], [@CIT0015], [@CIT0027], [@CIT0032], [@CIT0033]\] and 1 collected data retrospectively \[[@CIT0034]\]. Two of the studies used the same cohort of neonates but reported different outcomes \[[@CIT0028], [@CIT0029]\]. Four studies were conducted in the United States \[[@CIT0004], [@CIT0025], [@CIT0026], [@CIT0033]\], 4 in Sweden \[[@CIT0028]\], 1 in Kenya \[[@CIT0027]\], 1 in Mexico \[[@CIT0032]\], and 2 in Hong Kong \[[@CIT0015], [@CIT0034]\].

###### 

Characteristics of Included Studies

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study (year)                                 Study Design   Country     No. of Neonates With Confirmed Chlamydial Conjunctivitis   Primary Outcome(s)\                                                   Follow-Up Time(s)                                            No. Lost to Follow-Up   Intervention(s)
                                                                                                                                     Measured                                                                                                                                                   
  -------------------------------------------- -------------- ----------- ---------------------------------------------------------- --------------------------------------------------------------------- ------------------------------------------------------------ ----------------------- --------------------------------------------------------------------------
  Hammerschlag et al \[[@CIT0004]\] (1982)     NRS            USA         12                                                         Clinical cure, microbiological cure, complications, compliance        2 and 6 wk, 3 and 6 mo, and 1 year                           1                       Erythromycin\
                                                                                                                                                                                                                                                                                                50 mg/kg per day × 14 days

  Patamasucon et al \[[@CIT0025]\] (1982)      RCT^a^         USA         41                                                         Clinical cure, microbiological cure, adverse effects, compliance      1, 3, 7, 10, 14, 21, and 28 days                             12                      Erythromycin\
                                                                                                                                                                                                                                                                                                20, 30, or 40 mg/kg × 21 days

  Heggie et al \[[@CIT0026]\] (1985)           RCT^a^         USA         37                                                         Clinical cure, microbiological cure, adverse effects                  14 days and 4--6 wk                                          8                       Erythromycin\
                                                                                                                                                                                                                                                                                                50 mg/kg per day × 14 days

  Fransen et al \[[@CIT0027]\] (1986)          NRS            Kenya       22                                                         Clinical cure, microbiological cure, adverse effects                  7--10 and 30 days                                            5                       Erythromycin\
                                                                                                                                                                                                                                                                                                50 mg/kg per day × 10 days

  Sandström \[[@CIT0028]\] (1987)              NRS            Sweden      19                                                         Adverse effects                                                       0, 3, 4, 10, 18, and 32 days                                 NR                      Erythromycin\
                                                                                                                                                                                                                                                                                                50 mg/kg per day × 14 days

  Sandström et al \[[@CIT0029]\] (1988)        NRS            Sweden      33                                                         Clinical cure, microbiological cure, complications, compliance        1, 3, 4, 10, 14, 18, and 32 days and 2, 3, 4, 6, and 12 mo   9                       Erythromycin\
                                                                                                                                                                                                                                                                                                50 mg/kg per day × 14 days

  Stenberg et al \[[@CIT0030]\] (1990)         NRS            Sweden      45                                                         Clinical cure, microbiological cure, complications, adverse effects   1 mo and 1 year                                              16                      Erythromycin\
                                                                                                                                                                                                                                                                                                40--50 mg/kg per day × 14 days

  Stenberg et al \[[@CIT0031]\] (1991)         RCT^a^         Sweden      14                                                         Clinical cure, microbiological cure, complications, adverse effects   1 mo                                                         NR                      Erythromycin\
                                                                                                                                                                                                                                                                                                200 mg/day × 10 days

  Yescas-Buendía et al \[[@CIT0032]\] (1993)   NRS            Mexico      32                                                         Clinical cure, complications                                          5 and 6 days and 3 and 6 mo                                  0                       Erythromycin 30--40 mg/kg per day × 14 days (intravenously or orally)^b^

  Hammerschlag \[[@CIT0033]\] (1998)           NRS            USA         13                                                         Clinical cure, microbiological cure, adverse effects                  1--6 wk                                                      1                       Azithromycin 20 mg/kg single dose or × 3 days; erythromycin\
                                                                                                                                                                                                                                                                                                50 mg/kg per day × 14 days

  Chang et al \[[@CIT0034]\] (2006)            NRS            Hong Kong   19                                                         Clinical cure, complications, adverse effects                         2 wk and 6 mo                                                NR                      Erythromycin 50 mg/kg per day × 14 days

  Yip et al \[[@CIT0015]\] (2007)              NRS            Hong Kong   24                                                         Microbiological cure, complications                                   3 wk and 3 mo                                                4                       Erythromycin 50 mg/kg per day × 14 days
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: NR, not reported; RCT, randomized controlled trial; NRS, nonrandomized study.

^a^Only 1 treatment arm in which neonates received erythromycin was used in the analysis. The other treatment arm provided neonates with a treatment not covered in this review.

^b^Intravenous erythromycin was administered to 16 of 32 neonates with concomitant chlamydial pneumonia.

### Participants {#s12}

In total, 292 neonates with a confirmed microbiological diagnosis of neonatal chlamydial conjunctivitis were included. Sample sizes ranged from 12 to 45. Two studies \[[@CIT0025], [@CIT0031]\] included older infants, but they comprised less than 10% of the sample size; all other studies included neonates with disease onset in the first month of life. When reported, the distribution of male to female neonates seemed equal within the individual studies. Seven studies reported that neonates had received a previous prophylactic intervention such as topical silver nitrate solution \[[@CIT0004]\], erythromycin ointment \[[@CIT0004]\], tetracycline ointment \[[@CIT0025]\], chloramphenicol drops \[[@CIT0030], [@CIT0031]\], or fusidic acid eye ointment \[[@CIT0030]\]. One study reported the use of intramuscular injections of 50000 U of penicillin G potassium \[[@CIT0025]\]. The remaining study reports did not specify the type of prophylaxis given or did not report any prophylaxis use \[[@CIT0015], [@CIT0026], [@CIT0032]\]. However, in all cases, any previous antibiotics were stopped before starting the treatment of interest.

### Interventions {#s13}

[Table 1](#T1){ref-type="table"} provides detailed information about dosage regimens; erythromycin was the primary antibiotic used \[[@CIT0004], [@CIT0015], [@CIT0025], [@CIT0034]\]. The most common treatment regimen was the established standard of care \[[@CIT0035]\], erythromycin at 50 mg/kg per day orally in 4 divided doses daily for 14 days. One study \[[@CIT0033]\] analyzed the efficacy of 2 different durations of azithromycin treatment (single dose vs once daily for 3 days). None of the studies assessed the effects of trimethoprim.

Risk of Bias of Included Studies {#s14}
--------------------------------

Details of our risk-of-bias assessment are presented in [Supplementary Material](#sup1){ref-type="supplementary-material"}. Most of the studies objectively and accurately ascertained exposure of neonates to erythromycin either through secure hospital records or at clinic or trial visits and assessed clinical and microbiological cure outcomes according to the results of clinical examination and microbiological tests of cure. However, other outcomes, such as adverse effects, complications, and compliance, were likely not measured objectively or independently. Several studies were also at risk of bias as a result of their high percentage of loss to follow-up or lack of a statement regarding follow-up \[[@CIT0025], [@CIT0029], [@CIT0031]\]. Overall, the risk of bias in the included studies was very serious because of their high loss to follow-up and lack of objective assessment of most outcomes.

Effects of Interventions {#s15}
------------------------

[Table 2](#T2){ref-type="table"} provides a summary of the findings and a detailed assessment of the certainty of evidence for all treatments and critical outcomes in our meta-analysis. For most of the outcomes, the certainty of evidence is very low across the doses of erythromycin and azithromycin. We found serious risk of bias in all the studies and serious to very serious imprecision as a result of the small numbers of neonates in the trials. Considering the greater numbers of neonates in the studies that evaluated erythromycin at 50 mg/kg per day for 14 days and the large effects, the evidence for cure was of low certainty.

###### 

Summary of Findings for Outcomes of Neonatal Chlamydial Conjunctivitis Treatments (Presented as Pooled Proportions)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Findings                 Overall Certainty of Evidence^a^   Erythromycin % (95% CI); n/N   Azithromycin % (95% CI); n/N                                                                  
  ------------------------ ---------------------------------- ------------------------------ ------------------------------ -------------- --------------- --------------- --------------- ---------------
  Outcome                                                                                                                                                                                  

   Clinical cure           Low^b,c^\                          96\                            93\                            78\            100\            100\            60\             100\
                           ⊕⊕OO                               (92 to 101); 121/128           (78 to 108); 13/14             (60 to 96);\   (95 to 105);\   (93 to 107);\   (27 to 93);\    (82 to 118);\
                                                                                                                            14/18          32/32           22/22           3/5             7/7

   Microbiological cure    Low^b,c^\                          97\                            71\                            78\            NM              100\            60\             86\
                           ⊕⊕OO                               (94 to 100);\                  (50 to 93);\                   (60 to 96);\                   (93 to 107);\   (27 to 93);\    (61 to 110);\
                                                              124/132                        10/14                          14/18                          22/22           3/5             6/7

   Treatment relapse^d^    NA                                 2\                             NM                             6\             NM              14\             NM              NM
                                                              (−3 to 7);\                                                   (−7 to 18);\                   (−1 to 28);\                    
                                                              4/69                                                          1/18                           3/22                            

  Adverse effects                                                                                                                                                                          

   Gastrointestinal^e^     Very low^b,f^\                     14\                            43\                            7\             NM              18\             0\              0\
                           ⊕OOO                               (1 to 28);\                    (20 to 66);\                   (1 to 13);\                    (3 to 34);\     (−22 to 22);\   (−18 to 18);\
                                                              10/71                          6/14                           6/85                           4/22            0/5             0/7

   Pyloric stenosis        NA                                 0 (−8 to 8);\                  NM                             NM             NM              NM              NM              NM
                                                              0/19                                                                                                                         

  Complication                                                                                                                                                                             

   Conjunctival scarring   Very low^b,f^\                     6\                             NM                             NM             NM              NM              NM              NM
                           ⊕OOO                               (−1 to 12);\                                                                                                                 
                                                              4/70                                                                                                                         

   Antibiotic resistance   NM                                                                                                                                                              
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: n, number of events; N, total number of patients followed up; NA, not assessed; NM, not measured.

^b^Nonrandomized studies were at serious risk of bias because most outcomes were not measured objectively and there was high loss to follow-up; evidence was rated down by 2 levels.

^c^Imprecision resulted from small sample sizes and few events; however, the effects were large compared to those of no treatment and, therefore, the evidence was not rated down.

^d^Clinical and/or microbiological relapse.

^e^Includes diarrhea, watery stools, vomiting, and apparent abdominal pain.

^f^Imprecision resulted from small sample sizes and few events, and the evidence was rated down 1 level.

^a^Certainty of the evidence: high (++++), we are very confident that the true effect lies close to that of the estimate of the effect; moderate (+++O), we are moderately confident in the effect estimate (the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different); low (++OO), our confidence in the effect estimate is limited (the true effect may be substantially different from the estimate of the effect); very low (+OOO), we have very little confidence in the effect estimate (the true effect is likely to be substantially different from the estimate of effect).

Clinical and Microbiological Cure {#s16}
---------------------------------

### Erythromycin {#s17}

We pooled results from 7 studies that evaluated erythromycin at 50 mg/kg per day for 14 days (161 neonates) \[[@CIT0004], [@CIT0015], [@CIT0026], [@CIT0029], [@CIT0030], [@CIT0033], [@CIT0034]\]. This dose resulted in a clinical cure of 96% (95% CI, 92%--101%) and a microbiological cure of 97% (95% CI, 94%--100%) ([Figures 2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}). Four of 69 infants (2% \[95% CI, −3% to 7%\]) experienced a microbiological relapse after being treated with erythromycin at 50 mg/kg per day for 14 days, but none of the infants had a clinical relapse at 1 year \[[@CIT0004], [@CIT0029], [@CIT0030]\]. Yescas-Buendía et al \[[@CIT0032]\] treated infants with a lower dose of erythromycin (30--40 mg/kg per day for 14 days), and 100% (95% CI, 95%--105%) of the infants were clinically cured. Patamasucon et al \[[@CIT0025]\] also tested erythromycin at lower doses, including 20, 30, and 40 mg/kg per day for 21 days, and reported clinical and microbiological cure of 100% (95% CI, 93%--107%) after 7 days of treatment. However, 3 (14%) of these neonates either experienced a relapse or were reinfected after completing the 21-day treatment regimen \[[@CIT0025]\]. Two of these relapses were both clinical and microbiological, and 1 was only a microbiological relapse. The study report did not specify which neonates received which dose specifically. One study \[[@CIT0027]\] evaluated erythromycin at 50 mg/kg per day for a shorter duration of 10 days and reported a clinical and microbiological cure for 78% (95% CI, 60%--96%) of the neonates. Of 18 infants, 1 (6% \[95% CI, −7% to 18%\]) treated with erythromycin at 50 mg/kg per day for 10 days experienced a clinical and microbiological relapse \[[@CIT0027]\]. Another study \[[@CIT0031]\] used a fixed dosage of erythromycin (200 mg/day) for 10 days and reported a clinical cure of 93% (95% CI, 78%--108%) and a microbiological cure of 71.4% (95% CI, 50%--93%), the lowest microbiological cure found among all the interventions. This study did not weight-adjust the dose; however, 12 of the 14 neonates received a dosage that ranged from 49 to 54 mg/kg per day. When reported, neonates whose treatment failed across all studies were re-treated and cured with a second or, rarely, third course of erythromycin, unless they were lost to follow-up.

![Clinical cure data for erythromycin treatment. Abbreviations: CI, confidence interval; df, degrees of freedom; IV, inverse-variance method; SE, standard error.](piy06002){#F2}

![Microbiological cure data for erythromycin treatment. Abbreviations: CI, confidence interval; df, degrees of freedom; IV, inverse-variance method; SE, standard error.](piy06003){#F3}

### Azithromycin {#s18}

Five infants received 1 dose of azithromycin at 20 mg/kg, and 3 (60% \[95% CI, 27%--93%\]) of these 5 infants were both clinically and microbiologically cured after follow-up \[[@CIT0033]\]. The 2 infants who experienced treatment failure underwent re-treatment with erythromycin at 50 mg/kg per day for 14 days. However, 1 of these infants required 2 courses of erythromycin to recover fully \[[@CIT0033]\]. Of 7 infants, 6 (86% \[95% CI, 61%--110%\]) treated with azithromycin at 20 mg/kg per day for 3 days were microbiologically cured after treatment, and all of them were clinically asymptomatic. The remaining infant with culture-positive (both eye and nasopharyngeal swab) chlamydial conjunctivitis was re-treated with erythromycin and achieved both clinical and microbiological cure after the 14-day follow-up \[[@CIT0033]\]. The authors reported that the 3 infants whose culture results remained positive did not receive the entire dose of azithromycin successfully.

### Adverse Effects {#s19}

The most commonly reported adverse effects were related to the gastrointestinal tract \[[@CIT0025], [@CIT0027], [@CIT0028], [@CIT0030], [@CIT0031]\], including diarrhea, watery stools, vomiting, and apparent abdominal pain; the authors did not report whether the effects were severe or whether treatment was stopped as a result of the adverse effects. In the treatment group given erythromycin at 50 mg/kg per day for 14 days, 14% (95% CI, 1%--28%) of the neonates developed adverse gastrointestinal effects \[[@CIT0028], [@CIT0030]\]. Adverse gastrointestinal effects occurred in 43% (95% CI, 20%--66%) of the neonates treated with erythromycin at 200 mg/day for 10 days and 18% (95% CI, 3%--34%) of those treated with erythromycin at 20, 30, or 40 mg/kg per day for 21 days \[[@CIT0025], [@CIT0031]\]. The authors of the study that treated neonates with erythromycin at 50 mg/kg per day for 10 days reported that 7% (95% CI, 1%--13%) experienced adverse gastrointestinal effects \[[@CIT0027]\]. No adverse effects, including gastrointestinal adverse effects, were observed in the 12 infants treated with azithromycin \[[@CIT0033]\]. None of the 19 neonates treated with erythromycin at 50 mg/kg per day for 14 days experienced pyloric stenosis after 6 months of follow-up \[[@CIT0034]\]. No other studies reported or measured for pyloric stenosis.

### Complications {#s20}

Four studies assessed the development of pneumonia after treatment with antibiotics \[[@CIT0004], [@CIT0025], [@CIT0029], [@CIT0030]\], and 3 of these studies \[[@CIT0004], [@CIT0029], [@CIT0030]\] had a follow-up duration of 1 year (see [Table 1](#T1){ref-type="table"}), which is long enough to detect the occurrence of pneumonia (the typical age of onset is between 1 and 3 months) \[[@CIT0035]\]. Of 76 neonates, 1 (1% \[95% CI, −3% to 5%\]) treated with erythromycin at 50 mg/kg per day for 14 days developed pneumonia \[[@CIT0004], [@CIT0029], [@CIT0030]\] at one month after treatment and were treated with another 2-week course of erythromycin \[[@CIT0030]\]. None of the 22 neonates treated with erythromycin at 20, 30, or 40 mg/kg per day for 21 days developed pneumonia \[[@CIT0025]\]. Three studies assessed rates of conjunctival scarring \[[@CIT0028]\]. By pooling data from 2 studies, we found that 4 (6% \[95% CI, −3% to 17%\]) of 70 neonates treated with erythromycin at 50 mg/kg per day for 14 days developed conjunctival scarring \[[@CIT0029], [@CIT0030]\]. Ten studies reported nasopharyngeal infection \[[@CIT0004], [@CIT0025], [@CIT0033]\], which occurred in 118 (50.2%) of 235 neonates. Of 90 neonates treated with erythromycin at 50 mg/kg per day for 14 days, 4 (3% \[95% CI, −1% to 8%\]) had a nasopharynx specimen that they were culture positive for *Chlamydia trachomatis* \[[@CIT0004], [@CIT0015], [@CIT0026], [@CIT0029], [@CIT0030], [@CIT0033]\]. Of 5 neonates given erythromycin at 50 mg/kg per day for 10 days, 3 (60% \[95% CI, 27%--93%\]) had persistent nasopharyngeal infection \[[@CIT0027]\]; 0 of 6 given erythromycin at 20, 30, or 40 mg/kg per day for 21 days had persistent nasopharyngeal infection \[[@CIT0025]\]; and 3 (21% \[95% CI, 1%--41%\]) of 14 given erythromycin at 200 mg/day for 10 days \[[@CIT0031]\] had persistent nasopharyngeal infection. Only 1 neonate treated with azithromycin at 20 mg/kg per day given in a single dose and 1 (50% \[95% CI, 9%--91%\]) of 2 neonates treated with azithromycin at 20 mg/kg per day for 3 days had persistent nasopharyngeal infection \[[@CIT0033]\].

### Antibiotic Resistance {#s21}

We did not find any studies that measured antibiotic resistance.

### Compliance {#s22}

Only 2 studies reported compliance issues \[[@CIT0004], [@CIT0025]\]. Patamasucon et al \[[@CIT0025]\] measured the erythromycin content of serum and tears as an indicator of compliance. In that study, the authors reported that of the 22 neonates who received oral erythromycin, all of them had a detectable erythromycin level. However, the authors also reported that of all 53 neonates initially included in the study, 5 were excluded because of noncompliance, but they did not indicate who received topical or oral therapy. Hammerschlag et al \[[@CIT0004]\] reported 1 incident of noncompliance in which an infant received the prescribed therapy for only 5 days instead of 14 days.

DISCUSSION {#s23}
==========

Ours is the first systematic review and meta-analysis of treatments for neonatal chlamydial conjunctivitis. We included 12 studies that assessed the effects of erythromycin or azithromycin, but we found no randomized studies that directly compared different drugs and no studies that evaluated trimethoprim. The certainty of evidence is low to very low because of the high risk of bias and the imprecision of the results across the studies. Overall, we found very large effects for cure for some treatments. We found high proportions of clinical (96%) and microbiological (97%) cure when erythromycin at 50 mg/kg per day was given in 4 divided doses for 14 days. These effects are large when compared to those with topical therapy alone \[[@CIT0004], [@CIT0026]\]. Several studies assessed topical therapy alone \[[@CIT0004], [@CIT0025], [@CIT0026], [@CIT0028]\], and their microbiological cure ranged from 0% with chloramphenicol ointment \[[@CIT0028]\] to 78% with 1% erythromycin ophthalmic ointment. We found some data from small individual studies that suggest that lower doses or shorter courses of erythromycin might reduce the proportion of neonates cured, but the evidence is uncertain because of the very low-quality evidence. Adverse gastrointestinal effects, including diarrhea, watery stools, vomiting, and abdominal pain, can occur in 14% of neonates receiving erythromycin and might be higher when the dose of erythromycin is not adjusted to the infant's weight. The only complication noted across the studies was scarring of the conjunctiva, which occurred in 6% (95% CI, −3% to 17%) of the neonates treated with erythromycin at 50 mg/kg per day for 14 days. We found 1 study that examined the efficacy of azithromycin in 12 neonates \[[@CIT0033]\]. Although it seems that clinical and microbiological cure rates might be lower with azithromycin than with the standard dose of erythromycin, we are very uncertain in this result. Also, very few data regarding adverse effects and complications of azithromycin have been reported. Evidence on compliance was sparse; however, given the less-frequent dosing of azithromycin, it is possible that its use could improve compliance \[[@CIT0036]\]. No studies in this review measured antibiotic resistance, but recent evidence suggests that antibiotic resistance is not currently an issue with *C trachomatis* infection \[[@CIT0037], [@CIT0038]\].

Only 1 study reported the rate of pyloric stenosis; 0 of the 19 neonates who received erythromycin developed any signs or symptoms \[[@CIT0034]\]. Infantile hypertrophic pyloric stenosis typically presents between 3 and 8 weeks of age, and the length of follow-up in several of the studies was less than this time period \[[@CIT0025], [@CIT0027], [@CIT0028], [@CIT0031]\]. In addition, most of the included studies were published before 1999, the year in which the initial association between oral erythromycin and pyloric stenosis in infants after pertussis prophylaxis was elucidated \[[@CIT0039], [@CIT0040]\]. More recently, a study of a large retrospective cohort with more than 1 million infants with various infections revealed an increased risk of pyloric stenosis with both azithromycin and erythromycin \[[@CIT0041]\]. The authors of this study reported the highest risk in infants exposed before 2 weeks of age, and a slightly higher risk was found in infants given erythromycin than in those given azithromycin (adjusted odds ratios, 13.3 \[95% CI, 6.8--15.9\] and 8.3 \[95% CI, 2.6--26\], respectively). This result means that compared to the number of neonates between 0 and 14 days old who developed pyloric stenosis when not receiving any antimicrobial agent (approximately 2 of 1000), there might be 29 more neonates with pyloric stenosis when given erythromycin compared to 18 more when given azithromycin. Other studies also found an increased risk of pyloric stenosis after early exposure to erythromycin \[[@CIT0042]\].

There are some limitations of our review. First, this systematic review was restricted to studies in which the investigators confirmed neonatal chlamydial conjunctivitis microbiologically, but in many low- and middle-income countries, microbiological diagnosis is not feasible. Nevertheless, this review measures the best possible cure rates of the drug regimens in neonates who have chlamydial conjunctivitis. Given that we found primarily nonrandomized studies that evaluated the effects of 1 drug in 1 group of neonates, we pooled proportions across studies. However, we did not attempt to compare statistically the pooled proportions of different regimens of erythromycin to each other or compare azithromycin to erythromycin because of the small numbers of neonates across studies and the degree of indirectness. Overall, the results of our review provide a synthesis of the best available evidence for the treatment of neonatal chlamydial conjunctivitis.

In summary, there is evidence of low to very low certainty for the effects of erythromycin and azithromycin and no published evidence for trimethoprim. These findings have been used to inform the development of clinical practice guidelines for the treatment of neonatal conjunctivitis by the World Health Organization \[[@CIT0018]\]. In that guideline, the experts balanced the potential benefits and harms of erythromycin and azithromycin, the limited information about compliance, the costs, and the greater clinical experience with erythromycin to make a strong recommendation for the use of azithromycin rather than erythromycin to treat chlamydial conjunctivitis in neonates, primarily because of the serious risk of pyloric stenosis in neonates who are given erythromycin. However, several questions remain unanswered. Many important outcomes identified by clinical experts have not been measured in studies, such as pyloric stenosis and compliance to the different drug regimens. Research that directly compares azithromycin, erythromycin, and trimethoprim is needed to measure critical outcomes better. Indeed, routine prenatal screening and treatment of pregnant women is the best method for preventing neonatal chlamydial conjunctivitis. Nonetheless, given the significant global burden of chlamydial infection and the lack of routine prenatal screening and treatment in certain countries, this research is still necessary.
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